COVID19 Treatment: Rusan Pharma, 36 others get Gujarat FDCA nod for Azithromycin
Ahmedabad: The Gujarat Food and Drug Control Administration (FDCA) has granted permission to 37 pharmaceutical firms including Vega Biotec, Gujarat Medicraft, Care-well Healthcare, Curis Lifesciences Private Ltd, Galen Pharma, Rusan Pharma, and Unimed Pharma Ltd to manufacture antibiotic azithromycin (AZM).
The antibiotic is used in combination with hydroxychloroquine (HCQ) to treat fatal COVID19. Medical Dialogues had recently reported that a combination of hydroxychloroquine and azithromycin had been prescribed for severe patients requiring ICU management.
The demand for HCQ and AZM has surged with an increase in the number of COVID patients. However, this treatment line for COVID-19 was recently brought up in the apex by an NGO, People for Better Treatment' (PBT) seeking precautions from the side effects of the cocktail used and that the doctors should explain to the patient about the risk involved in the particular line of treatment and take his or her consent.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.